Methods that may work well for recruiting and retaining white patients for clinical trials may need to be adjusted to maximize the involvement of patients from other ethnic backgrounds. At Biocom California’s Let’s Talk About series, panelists discussed the benefits and best practices for adding diversity to clinical trials.
Shares of Relmada Therapeutics Inc. (NASDAQ:RLMD) plummeted 77% to close at 63 cents Dec. 4 after a pre-planned interim analysis prompted the independent data monitoring committee to conclude the phase III Reliance II study testing REL-1017 in major depressive disorder is likely to fail, leaving the future of the NMDA receptor channel blocker in doubt while the company looks ahead to an earlier-stage psilocybin-based program targeting metabolic disease.
Although head-to-head results on tolerability were missing from the company’s data release, Eli Lilly and Co. said its U.S. FDA-approved weight-loss drug Zepbound (tirzepatide) beat the also-cleared Novo Nordic A/S compound Wegovy (semaglutide) in a phase IIIb study comparing the two.
South Korean billionaire and chairman of Celltrion Group Jungjin Seo is returning Celltrion Inc. to its contract manufacturing organization (CMO) roots, as it relies on biosimilar sales to anchor the company in a fiercely competitive novel drug R&D arena.
After raising AU$40 million (US$25.9 million) earlier this year to advance lead candidate VP-001 for treating retinitis pigmentosa type 11, PYC Therapeutics is now advancing PYC-003 to the clinic for polycystic kidney disease.
Janux Therapeutics Inc. CEO David Campbell said the firm will be talking with the U.S. FDA about “what we may or may not be able to do [in order to get JANX-007] to patients more rapidly,” though he noted that the agency has “primarily been focused on overall survival” in considering prostate cancer drugs, so more work on that endpoint may be required. “We’ll keep that in mind,” he said.
Arovella Therapeutics Ltd. is heading toward the clinic with its lead product, ALA-101, which consists of a chimeric antigen receptor (CAR) targeting CD19 and invariant natural killer T (iNKT) cells.
An artificial intelligence-powered contactless monitoring device developed by Albus Health Ltd. can detect signs of asthma attacks in children up to five days before they occur.
Arovella Therapeutics Ltd. is heading toward the clinic with its lead product, ALA-101, which consists of a chimeric antigen receptor (CAR) targeting CD19 and invariant natural killer T (iNKT) cells.
In October 2024, BioWorld logged 219 clinical trial updates, marking a decrease from 252 in September but a rise from 92 in August. The month featured 14 positive phase III trial outcomes and one unsuccessful trial.
RSS
